Alexza Pharma (ALXA) AZ-002 Meets Primary Endpoint; Upside Visualized In TubeMogul (TUBE)


Shares of Alexza Pharmaceuticals Inc. (Nasdaq:ALXA) soared more than 35% in after-hours trading Monday as the company said that a Phase 2a study evaluating efficacy and safety of its product candidate AZ-002 for acute repetitive seizures in epilepsy patients had succeeded in meeting its primary endpoint – according to interim data -.

ALXA stock closed at $0.878, down $0.022 (or -2.44%), and 53,242 of its shares exchanged hands during the regular session

Alexza Pharmaceuticals, focused on the development of proprietary products for the acute treatment of central nervous system conditions, has 19.58M Shares Outstanding, Market Capitalization (intraday) of $17.19M and ALXA stock 52-week range is from $0.80 to $2.68 per share



Investment analysts at SunTrust initiated coverage on TubeMogul, Inc. (Nasdaq:TUBE) stock with a Buy rating and a price target of $16.00, representing an upside potential of more than 19% over its price at close on Monday of $13.41 per share

110,550 shares of the company were traded during the day, decreased activity versus its average volume (3m) of 215,178

TubeMogul, a leading enterprise software company for brand advertising, has 35.05M Shares Outstanding, Market Capitalization (intraday) of $469.99M and TUBE stock one-year range is between $9.11 and $23.83 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at